Ketamine is a promising therapeutic option in treatment-resistant depression (TRD). The
acute efficacy of ketamine in TRD has been demonstrated in replicated randomised …

Objective The current meta‐analysis examines the effects of ketamine infusion on
depressive symptoms over time in major depressive disorder (MDD) and bipolar disorder …

BACKGROUND: Despite widely reported clinical and preclinical studies of rapid
antidepressant actions of glutamate N-methyl-D-aspartate (NMDA) receptor antagonists …

Pharmacologic Effects of CI-581, a New Dissociative Anesthetic, in Man. By EF Domino, P.
Chodoff, G. Corssen. Clin Pharmacol Ther 1965; 6: 279–91. Reprinted by permission from …

Since publication of the first randomized controlled trial describing rapid antidepressant
effects of ketamine, several reports have confirmed the potential utility of this dissociative …

Background Clinical studies report that scopolamine, an acetylcholine muscarinic receptor
antagonist, produces rapid antidepressant effects in depressed patients, but the …

Several studies have supported the idea that ionotropic glutamate N-methyl-d-aspartate
receptor (NMDA) is an important player in the etiology of psychopathologies, such as anxiety …

Preclinical as well as limited clinical studies indicate that ketamine, a non-competitive
glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, may exert a quick and …

Background: Depression and anxiety are prevalent and undertreated in patients receiving
hospice care. Standard antidepressants do not work rapidly or often enough to benefit most …

Depression is a neuropsychiatric disorder affecting a huge percentage of the active
population especially in developed countries. Research has devoted much of its attention to …